Remove Development Remove Genetic Engineering Remove Genome
article thumbnail

Leading innovators in transcription factors for AAV for the pharmaceutical industry

Pharmaceutical Technology

AAV genomes are highly compact, with overlapping coding regions, alternate splicing schemes, and multiple transcription initiation codons. There are two main genes in the AAV genome, rep and cap, which encode nine different proteins. Encoded Therapeutics develops gene therapies for the treatment of severe genetic disorders.

Gene 262
article thumbnail

ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement

BioTech 365

ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement Nobel prize winning CRISPR technology to be applied in development of genetically engineered animal models DUBLIN & SHIZUOKA, Japan–(BUSINESS WIRE)–ERS Genomics Limited, … Continue reading →

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bringing in Light Genome Editing Techniques: ZFN, TALEN and Meganucleases

Roots Analysis

Presently, there are several companies and universities, which are exploring the potential of different gene editing technologies beyond CRISPR for basic research, and the development of gene editing solutions. Genome Editing is a way of making changes in the DNA. Type of Genome Editing: Zinc-Finger Nuclease.

article thumbnail

ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement

BioTech 365

ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement Nobel prize winning CRISPR technology to be applied in development of genetically engineered cell and animal models DUBLIN & TOKUSHIMA, Japan–(BUSINESS WIRE)–ERS … Continue reading →

article thumbnail

Leading innovators in gene splicing using nucleases for the pharmaceutical industry

Pharmaceutical Technology

Innovation S-curve for the pharmaceutical industry Gene splicing using nucleases is a key innovation area in the pharmaceutical industry Nucleases play a fundamental role in the field of recombinant DNA technology, or genetic engineering. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.

article thumbnail

Leading innovators in zinc-finger nucleases for the pharmaceutical industry

Pharmaceutical Technology

Innovation S-curve for the pharmaceutical industry Zinc-finger nucleases is a key innovation area in pharmaceutical Zinc finger nucleases (ZFNs) are tools used in genetic engineering to cleave a chosen genomic sequence. The company's lead asset involving this technology is isaralgagene civaparvovec (ST 920).

Genetics 130
article thumbnail

A history of blood cancer treatment

pharmaphorum

Similar to Newbury, McBean – known to be a highly respected tradesman – developed fatigue and severe pain from weak and easily broken bones. During this period, Nobel prize-winning German scientist Paul Ehrlich developed his lock-key hypothesis of molecules that specifically bind to cell receptors.